| Autor: |
Lauren Krupp, Brenda Banwell, Tanuja Chitnis, Kumaran Deiva, Jutta Gaertner, Angelo Ghezzi, Peter Huppke, Emmanuelle Waubant, Virginia DeLasHeras, Amin Azmon, Rajesh Karan |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
BMJ neurology open. 4(1) |
| ISSN: |
2632-6140 |
| Popis: |
BackgroundIn the PARADIGMS Study, fingolimod demonstrated superior efficacy versus interferon (IFN) β-1a and comparable overall incidence of adverse events but slightly higher rate of serious adverse events in patients with paediatric-onset multiple sclerosis (PoMS). Here, we report the health-related quality of life (HRQoL) outcomes from PARADIGMS.MethodsPatients with PoMS (N=215; aged 10–ResultsTreatment with fingolimod showed improvements versus IFN β-1a on the PedsQL scale in both the self-reported and parent-reported Total Scale Scores (4.66 vs −1.16, p≤0.001 and 2.71 vs −1.02, p≤0.05, respectively). The proportion of patients achieving a clinically meaningful improvement in the PedsQL Total Scale Score was two times higher with fingolimod versus IFN β-1a per the self-reported scores (47.5% vs 24.2%, p=0.001), and fingolimod was favoured versus IFN β-1a per the parent-reported scores (37.8% vs 24.7%, p=non-significant). Group differences in self-reported Total Scale Scores in favour of fingolimod were most pronounced among patients who had ≥2 relapses in the year prior to study entry or who showed improving or stable Expanded Disability Status Scale scores during the study.ConclusionFingolimod improved HRQoL compared with IFN β-1a in patients with PoMS as evidenced by the self-reported and parent-reported PedsQL scores. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
